Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer

Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news